NASDAQ:PMD

Psychemedics Stock Forecast, Price & News

$7.36

+0.13 (+1.80 %)

(As of 07/27/2021 12:00 AM ET)

Add

Compare

Today's Range

$7.25

▼

$7.57

50-Day Range

$6.55

▼

$8.25

52-Week Range

$3.58

▼

$8.36

Volume61,962 shs

Average Volume30,141 shs

Market Capitalization$40.77 million

P/E RatioN/A

Dividend YieldN/A

Beta0.79

30 days | 90 days | 365 days | Advanced Chart

Receive PMD News and Ratings via Email

Sign-up to receive the latest news and ratings for Psychemedics and its competitors with MarketBeat's FREE daily newsletter.

About Psychemedics

Psychemedics Corp. engages in the provision of drug testing services through the analysis of hair samples. It specializes in a five panel drug testing process for cocaine, opioids, Phenyclidine, amphetamines, and marijuana. It offers workplace, school, and personal drug testing services. The company was founded by Werner Baumgartner and Annette Baumgartner on September 24, 1986 and is headquartered in Acton, MA.

Psychemedics (NASDAQ:PMD) Share Price Crosses Above 200 Day Moving Average of $0.00
July 27, 2021 | americanbankingnews.com

Psychemedics (NASDAQ:PMD) Stock Passes Above Two Hundred Day Moving Average of $0.00
July 13, 2021 | americanbankingnews.com

Did Psychemedics Corporation (NASDAQ:PMD) Insiders Buy Up More Shares? - Yahoo Finance
July 1, 2021 | finance.yahoo.com

Did Psychemedics Corporation (NASDAQ:PMD) Insiders Buy Up More Shares?
July 1, 2021 | finance.yahoo.com

The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda - Benzinga
June 15, 2021 | benzinga.com

Is Psychemedics Corp. (PMD) A Good Stock To Buy? - Yahoo Finance
June 14, 2021 | finance.yahoo.com

Is Psychemedics Corp. (PMD) A Good Stock To Buy?
June 14, 2021 | finance.yahoo.com

Montana Advisors Writes Open Letter to Psychemedics
June 1, 2021 | businesswire.com

Psychemedics Corporation Reports First Quarter 2021 Financial Results
May 10, 2021 | finance.yahoo.com

Have Insiders Been Buying Psychemedics Corporation (NASDAQ:PMD) Shares This Year?
May 2, 2021 | nasdaq.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PMD
Previous Symbol
CUSIPN/A
CIK806517
Webwww.psychemedics.com
Phone(978) 206-8220
Employees138
Year FoundedN/A

Sales & Book Value

Annual Sales$21.36 million
Price / Sales1.91
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.26 per share
Price / Book3.26

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares5,536,000
Market Cap$40.77 million
Next Earnings Date8/11/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.09 out of 5 stars

Medical Sector

1480th out of 2,218 stocks

Medical Laboratories Industry

30th out of 41 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Psychemedics.

3.8 Community Rank

Outperform Votes
Psychemedics has received 142 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Psychemedics has received 47 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Psychemedics has received 75.13% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Psychemedics and other stocks. Vote “Outperform” if you believe PMD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PMD will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Psychemedics does not currently pay a dividend.
Dividend Growth
Psychemedics does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Psychemedics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 13.30% of the stock of Psychemedics is held by insiders.
Percentage Held by Institutions
33.64% of the stock of Psychemedics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Psychemedics is -11.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Psychemedics is -11.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Psychemedics has a P/B Ratio of 3.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Psychemedics (NASDAQ:PMD) Frequently Asked Questions

What stocks does MarketBeat like better than Psychemedics?

Wall Street analysts have given Psychemedics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Psychemedics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Psychemedics' next earnings date?

Psychemedics is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for Psychemedics.

How were Psychemedics' earnings last quarter?

Psychemedics Co. (NASDAQ:PMD) announced its quarterly earnings results on Monday, May, 10th. The company reported $0.01 EPS for the quarter. The firm earned $5.71 million during the quarter. Psychemedics had a negative net margin of 18.51% and a negative trailing twelve-month return on equity of 27.72%.
View Psychemedics' earnings history.

How has Psychemedics' stock been impacted by Coronavirus?

Psychemedics' stock was trading at $6.95 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PMD stock has increased by 6.0% and is now trading at $7.3650.
View which stocks have been most impacted by COVID-19.

Who are Psychemedics' key executives?

Psychemedics' management team includes the following people:

Raymond C. Kubacki, Chairman, President & Chief Executive Officer
Charles M. Doucot, Executive Vice President
Sarah E. Ashby, Vice President & General Counsel
Andrew Limbek, Vice President & Controller
Michael I. Schaffer, Vice President-Laboratory Operations

What is Raymond C. Kubacki Jr.'s approval rating as Psychemedics' CEO?

6 employees have rated Psychemedics CEO Raymond C. Kubacki Jr. on Glassdoor.com. Raymond C. Kubacki Jr. has an approval rating of 67% among Psychemedics' employees.

Who are some of Psychemedics' key competitors?

Some companies that are related to Psychemedics include Enzo Biochem (ENZ), Progenity (PROG), Viridian Therapeutics (VRDN), OpGen (OPGN), Vyant Bio (VYNT), Biocept (BIOC), AnPac Bio-Medical Science (ANPC), CannLabs (CANL), American Shared Hospital Services (AMS), American Shared Hospital Services (AMS), Avant Diagnostics (AVDX), CBA Florida (CBAI), Zicix (ZICX), First Choice Healthcare Solutions (FCHS) and PotNetwork (POTN).
View all of PMD's competitors.

What other stocks do shareholders of Psychemedics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Psychemedics investors own include Zynerba Pharmaceuticals (ZYNE), Dominion Energy (D), Sorrento Therapeutics (SRNE), AT&T (T), AbbVie (ABBV), (CGC), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pattern Energy Group (PEGI) and Simon Property Group (SPG).

What is Psychemedics' stock symbol?

Psychemedics trades on the NASDAQ under the ticker symbol "PMD."

How do I buy shares of Psychemedics?

Shares of PMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Psychemedics' stock price today?

One share of PMD stock can currently be purchased for approximately $7.37.

How much money does Psychemedics make?

Psychemedics has a market capitalization of $40.77 million and generates $21.36 million in revenue each year.

How many employees does Psychemedics have?

Psychemedics employs 138 workers across the globe.

What is Psychemedics' official website?

The official website for Psychemedics is www.psychemedics.com.

Where are Psychemedics' headquarters?

Psychemedics is headquartered at 289 GREAT ROAD Suite 200, ACTON MA, 01720.

How can I contact Psychemedics?

Psychemedics' mailing address is 289 GREAT ROAD Suite 200, ACTON MA, 01720. The company can be reached via phone at (978) 206-8220.

This page was last updated on 7/27/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here